Interacting drugs Interacting active principles Interaction severity Interaction effects
COVID-19 medication with other COVID-19 therapies HCQ-azithromycin Moderate Increased risk of QT ECG prolongation.
HCQ-lopinavir/ritonavir Major Increased risk of QT ECG prolongation.
HCQ-tocilizumab Moderate Increased risk of peripheral neuropathy.
Lopinavir/ritonavir-azithromycin Moderate Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-darunavir/cobicistat Moderate Altered blood levels and effects of both medications due to darunavir/cobicistat inhibition and lopinavir inhibition or induction of CYP450 3A4.
COVID-19 medication with CNS medications Azithromycin-citalopram Major Increased risk of QT ECG prolongation.
Azithromycin-haloperidol Major Increased risk of QT ECG prolongation.
Azithromycin-olanzapine Moderate Increased risk of QT ECG prolongation.
Azithromycin-promazine Moderate Increased risk of QT ECG prolongation.
Azithromycin-quetiapine Moderate Increased risk of QT ECG prolongation.
Azithromycin-trazodone Moderate Increased risk of QT ECG prolongation.
Darunavir/cobicistat-alprazolam Moderate Increased blood levels of alprazolam due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-clonazepam Moderate Increased blood levels of clonazepam due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-midazolam Major Increased blood levels of midazolam due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-risperidone Moderate Increased blood levels of risperidone to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-sertraline Moderate Decreased blood levels and effects of sertraline.
Enoxaparin-citalopram Moderate Increased risk of bleeding.
Enoxaparin-sertraline Moderate Increased risk of bleeding.
HCQ-citalopram Major Increased risk of QT ECG prolongation.
HCQ-codeine Moderate Increased risk of codeine reduced efficacy.
HCQ-haloperidol Major Increased risk of QT ECG prolongation.
HCQ-olanzapine Moderate Increased risk of QT ECG prolongation.
HCQ-promazine Major Increased risk of QT ECG prolongation.
HCQ-quetiapine Major Increased risk of QT ECG prolongation.
HCQ-risperidone Moderate Increased risk of QT ECG prolongation.
HCQ-sertraline Moderate Increased risk of QT ECG prolongation.
HCQ-trazodone Major Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-citalopram Major Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-haloperidol Major Increased risk of QT ECG prolongation and increased blood levels of haloperidol due to lopinavir/ritonavir inhibition of CYP450 2D6.
Lopinavir/ritonavir-olanzapine Moderate Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-promazine Moderate Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-quetiapine Major Increased blood levels of quetiapine due to lopinavir/ritonavir inhibition of CYP450 3A4 and increased risk of QT ECG prolongation.
Lopinavir/ritonavir-risperidone Moderate Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-sertraline Moderate Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-valproic acid Moderate Reduced blood levels of valproate due to lopinavir/ritonavir induction of glucuronosyltransferases.
Tocilizumab-amlodipine Moderate Decreased blood levels of amlodipine.
Tocilizumab-clonazepam Moderate Decreased blood levels of clonazepam.
Tocilizumab-midazolam Moderate Decreased blood levels of midazolam.
COVID-19 medication with CV medications Azithromycin-atorvastatin or simvastatin Moderate Increased blood levels of atorvastatin and increased risk of liver damage and myopathy due to azithromycin inhibition of CYP450 3A4.
Azithromycin-sertraline Moderate Increased risk of QT ECG prolongation.
Azithromycin-warfarin Moderate Increased risk of bleeding.
Darunavir/cobicistat-amiodarone Major Increased risk of QT ECG prolongation due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-amlodipine Moderate Increased blood levels of amlodipine due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-apixaban Major Increased blood levels of apixaban and increased risk of bleeding due to darunavir/cobicistat inhibition of CYP450 3A4 and P-glycoprotein.
Darunavir/cobicistat-atorvastatin or simvastatin Major Increased blood levels of atorvastatin and increased risk of liver damage and myopathy due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-nebivolol Moderate Increased blood levels of bisoprolol due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-rivaroxaban Major Increased blood levels of rivaroxaban and increased risk of bleeding due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-warfarin Moderate Altered blood levels of warfarin.
Enoxaparin-amiodarone Major Increased risk of bleeding.
Enoxaparin-apixaban Major Increased risk of bleeding.
Enoxaparin-clopidogrel Major Increased risk of bleeding.
Enoxaparin-losartan or valsartan Moderate Increased risk of hyperkalaemia.
Enoxaparin-perindopril Moderate Increased risk of hyperkalaemia.
Enoxaparin-warfarin Major Increased risk of bleeding.
HCQ-amiodarone Major Increased risk of QT ECG prolongation.
HCQ-atorvastatin or simvastatin Moderate Increased risk of peripheral neuropathy.
Lopinavir/ritonavir-apixaban Major Increased blood levels of apixaban and increased risk of bleeding due to ritonavir lopinavir/inhibition of CYP450 3A4 and P-glycoprotein.
Lopinavir/ritonavir-atorvastatin or simvastatin Major Increased blood levels of atorvastatin and increased risk of liver damage and myopathy due to lopinavir/ritonavir inhibition of CYP450 3A4.
Lopinavir/ritonavir-bisoprolol Moderate Increased risk of PR ECG prolongation.
Lopinavir/ritonavir-verapamil Moderate Increased risk of hypotension and of PR ECG prolongation.
Tocilizumab-atorvastatin Moderate Decreased levels of atorvastatin.
COVID-19 medication with other medications Azithromycin-loperamide Moderate Increased risk of QT ECG prolongation.
Darunavir/cobicistat-betamethasone Moderate Increased blood levels of betamethasone due to darunavir/cobicistat inhibition of CYP450 3A4.
Darunavir/cobicistat-clopidogrel Major Decreased efficacy of clopidogrel due to darunavir/cobicistat inhibition of CYP450 3A4/5, 1A2, 2B6.
Darunavir/cobicistat-dutasteride Moderate Increased blood levels of dutasteride.
Darunavir/cobicistat-ruxolitinib Major Increased blood levels of ruxolitinib due to darunavir/cobicistat inhibition of CYP450 3A4.
HCQ-bicalutamide Moderate Increased risk of QT ECG prolongation.
HCQ-fluticasone propionate/vilanterol Moderate Increased risk of QT ECG prolongation.
HCQ-gliclazide Moderate Increased risk of hypoglycaemia.
HCQ-linezolid Moderate Increased risk of neuropathy.
HCQ-loperamide Moderate Increased risk of QT ECG prolongation.
Lopinavir/ritonavir-betamethasone Moderate Increased blood levels of betamethasone due to lopinavir/ritonavir inhibition of CYP450 3A4.
Lopinavir/ritonavir-clopidogrel Major Decreased efficacy of clopidogrel due to lopinavir/ritonavir inhibition of CYP450 3A4/5, 1A2, 2B6.
Lopinavir/ritonavir-dutasteride Moderate Increased blood levels of dutasteride due to lopinavir/ritonavir inhibition of CYP450 3A4.
Lopinavir/ritonavir-fluticasone propionate/vilanterol Major Increased exposure to fluticasone propionate and vilanterol due to lopinavir/ritonavir inhibition of CYP450 3A4 and increased risk of QT ECG prolongation.
Lopinavir/ritonavir-gliclazide Moderate Increased risk of hyperglycaemia.
Lopinavir/ritonavir-insulin Moderate Increased risk of insulin inefficacy.
Lopinavir/ritonavir-levothyroxine Moderate Reduced blood levels of thyroxine due to lopinavir/ritonavir induction of glucuronosyltransferase.
Lopinavir/ritonavir-metformin Moderate Increased risk of hyperglycaemia.
Lopinavir/ritonavir-methylprednisolone Major Increased blood levels of methylprednisolone due to lopinavir/ritonavir inhibition of CYP450 3A4.
Lopinavir/ritonavir-tamsulosin Major Increased blood levels of tamsulosin due to lopinavir/ritonavir inhibition of CYP450 3A4 and 2D6; increased risk of hypotension and priapism.
Lopinavir/ritonavir-vildagliptin Moderate Increased risk of hyperglycaemia.